Abstract:HepatoBiliary Surg Nutr 2020;9(6):794-796 | http://dx.doi.org/10.21037/hbsn.2020.03.24 Liver cancer was ranked the sixth most commonly diagnosed cancer with the fourth leading cause of cancer-related deaths worldwide in 2018 (1). Notably, hepatocellular carcinoma (HCC) constitutes 75–85% among all the liver cancer cases, and ranks first morbidity and mortality of malignancies in Chinese males under 60. Due to hypervascularity in liver and high heterogeneity, HCC was regarded as an aggressive disease. Recent clinical trials focusing on resection and transplantation after targeted therapy for advanced HCC show encouraging results. However, the adjuvant therapy for patients with high risk of recurrence after surgery still raises attention. Currently, emerging evidence suggested that the crosstalk between tumor cells and the microenvironment plays a pivotal role in tumorigenesis and metastasis. The tumor microenvironment of HCC provides tumor cells with necessary conditions for their sustained growth, invasion and metastasis. It is typically characterized by dysregulated immune network, sustained injury and regeneration, angiogenesis, inflammation and metabolic reprogramming. These aforementioned characteristics raise attention to the important role of infiltrating immune cell profile and tumor stroma in microenvironmental regulation. According to the immune cell subset and proportion, HCC could be classified into different immune subtypes, for example, Sia’s “immune class/ exclusion” and Kurebayashi’s “immune high/mid/low”. Zhang et al. further identified three novel distinctive HCC subtypes with immunocompetent, immunodeficient, and immunosuppressive features (2). Immunocompetent and immunosuppressive subtype were characterized by robust immune cell infiltration and upregulated immune checkpoint molecules. These two subtypes, as well as the “immune class” and “immune-high subtype”, displayed significant increase in immune cells infiltration and better responsiveness to immunotherapy. Tumor stroma and vasculature could also cause considerable impact on tumor progression. Cancer-associated fibroblasts (CAFs) can result in a robust stromal reaction characterized by fibrotic extracellular matrix and make tumor cells convert to aggressive and immune-excluded phenotype via transforming growth factor-β (TGF-β) signaling pathway (3). Tumor-associated vasculature is another main hallmark of cancers. Endothelial cells (ECs) of the tumor vasculature can not only inhibit anti-tumor immunity by immune cells regulation and elimination, but also help to create a proangiogenic microenvironment via vascular endothelial growth factor (VEGF) signaling pathway (4). The disorganized tumor vasculature could remodel a special microenvironment characterized by hypoxia, acidosis, and high interstitial pressure, which both support tumor cells proliferation and structure a physical barrier for infiltrating immune cells (5). Furthermore, the interaction between different components relies on the regulation of chemokines and cytokines, which play essential roles in recruiting immune cells and maintaining cancer and stromal cell biology (6). In another word, these microenvironmental populations profoundly influence the tumor immune and metabolic homeostasis, which suggests immunometabolism as a novel perspective of HCC microenvironment. Editorial

IL-17A Secreted from Lymphatic Endothelial Cells Promotes Tumorigenesis by Up-regulation of PD-L1 in Hepatoma Stem Cells.

IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells

Infiltrating Regulatory T Cells Promote Invasiveness of Liver Cancer Cells Via Inducing Epithelial-Mesenchymal Transition

Targeting tumor microenvironment as a treatment strategy for hepatocellular carcinoma

Interleukin 35 Activates Intratumor Neovascularization Via Enhanced Secretion of FGF2 in Hepatocellular Carcinoma Through The Recruitment of Neutrophils, and Blocking it Could Facilitate The Efficacy of The PD-1 Antibody

IL-17 Induces AKT-dependent IL-6/JAK2/STAT3 Activation and Tumor Progression in Hepatocellular Carcinoma

IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer

High Expression of Il-17 and Il-17re Associate with Poor Prognosis of Hepatocellular Carcinoma

IDDF2019-ABS-0174 Targeting Monocyte-Intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma

IL-23 Promotes the Development of Hepatocellular Carcinoma Through the Induction of IL-17-producing ILC3 (TUM10P.1044)

NCR− Group 3 Innate Lymphoid Cells Orchestrate IL-23/IL-17 Axis to Promote Hepatocellular Carcinoma Development

Interleukin‐17A educated hepatic stellate cells promote hepatocellular carcinoma occurrence through fibroblast activation protein expression

IL-17 Affects the Progression, Metastasis, and Recurrence of Laryngeal Cancer via the Inhibition of Apoptosis through Activation of the PI3K/AKT/FAS/FASL Pathways

Il-17a Plays A Critical Role In The Pathogenesis Of Liver Fibrosis Through Hepatic Stellate Cell Activation

Interleukin-17 Promotes Mouse Hepatoma Cell Proliferation by Antagonizing Interferon-Γ

Data from Membrane IL1α Inhibits the Development of Hepatocellular Carcinoma Via Promoting T- and NK-cell Activation

Hepatic Stellate Cells Enhance Liver Cancer Progression by Inducing Myeloid-Derived Suppressor Cells through Interleukin-6 Signaling

Membrane Il1 Alpha Inhibits the Development of Hepatocellular Carcinoma Via Promoting T- and Nk-Cell Activation

Hepatoma Cell-Intrinsic TLR9 Activation Induces Immune Escape Through PD-L1 Upregulation in Hepatocellular Carcinoma

Interleukin-17 programs liver progenitor cell transformation into cancer stem cells through mir-122 downregulation with increased risk of primary liver cancer initiation

IL-17a promotes hepatocellular carcinoma by increasing FAP expression in hepatic stellate cells via activation of the STAT3 signaling pathway